Back to all announcements

DJ Rutherford Health PLC Meeting rising demand of proton beam therapy

TIDMRUTH

RNS Number : 8958B

Rutherford Health PLC

04 February 2020

Training oncologists to meet rising demand of proton beam therapy

Newport, 04 February 2020: The Rutherford Cancer Centres have announced that they have treated over 100 patients with proton beam therapy and trained over 65 oncologists in the treatment of proton therapy to meet the rising demand for the pioneering treatment in the UK.

Proton beam therapy, a form of radiotherapy that delivers heavily charged protons in a more targeted manner to reduce damage to peripheral tissue and organs, was introduced in the UK in 2018 by the Rutherford Cancer Centre South Wales and the number of patients treated has increased significantly.

Rutherford Health commissioned a bespoke training programme with The Perelman School of Medicine at the University of Pennsylvania and IBA, the leading proton beam therapy solutions manufacturer, to train NHS oncologists. The programme, Proton Therapy Clinical Education, offers trained oncologists the opportunity to obtain practicing privileges to work in the Rutherford Cancer Centre's network of proton beam therapy facilities.

The programme involves UK oncologists gaining practical experience in Penn's Roberts Proton Therapy Center - one of the world's leading centres of proton therapy research and expertise.

There are three fully operational Rutherford Cancer Centres in Wales, Reading and Northumberland with a fourth due to open in Liverpool.

The centres have treated over 100 patients with high energy proton beam therapy for various cancers including brain, head and neck, lung, pancreas, oesophagus, sarcoma, bladder, prostate and breast.

The rising demand for proton beam therapy comes on the back of a recent ground-breaking study involving over 1,500 patients which found that proton beam therapy can be as effective at treating certain types of cancer but with significantly fewer side effects.

Mike Moran, CEO of Rutherford Health PLC which oversees the network of Rutherford Cancer Centres, said: "Just one and a half years ago, there were no proton beam therapy facilities in the UK. Today, the Rutherford network has treated over 100 patients with proton beam therapy. That is a remarkable turnaround."

"The development of our centres and the expansion of proton beam therapy provision throughout the UK clearly indicates that there is strong demand for this treatment. Our oncologist training programme has been a crucial driver in that development process, ensuring patient treatment is performed in a safe and efficient manner across the board."

"In addition to contributing to wider growth in UK oncology, the programme incorporates a peer review system that ensures all treatment plans receive oversight from Penn's world-leading experience and expertise. This has also allowed us to align the use of proton therapy with that of Europe and the USA."

Dr Shanmugasundaram Ramkumar, who went through the programme and is now an oncologist at the Rutherford Cancer Centre in Reading, said: "The PBT training offered at Penn was concise and meets the needs of oncologists unfamiliar with PBT planning and treatment for a variety of cancers."

Rutherford Health hopes to widen access to precision radiotherapy including proton beam therapy and thereby significantly enhance patient outcomes as well as overall quality of life for cancer patients across the UK.

Contacts

 
Rutherford Health Plc 
Michael Moran, Chief Executive Officer                      Tel: +44 (0) 16 3381 
                                                                            0661 
 
 
Grant Thornton (Corporate Adviser)                          Tel: +44 (0) 20 7383 
                                                                            5100 
Colin Aaronson/ Jamie Barklem/ Niall 
 McDonald 
 
Media House International 
Ramsay Smith                            07788 414 856 or Ramsay@mediahouse.co.uk 
 

Notes to editors:

For further information please contract Ramsay Smith (ramsay@mediahouse.co.uk) or Ibrahim Khalil (ibrahim@mediahouse.co.uk) on: 020 7710 0020

About the Rutherford Cancer Centres

The Rutherford Cancer Centres are at the forefront of providing advanced cancer care and creating a better future for cancer patients. The centres provide an all-encompassing cancer service, delivering world-class imaging, chemotherapy, immunotherapy, radiotherapy and proton beam therapy treatment.

The Rutherford Cancer Centre South Wales struck a landmark partnership with the Welsh Government last year which sees adult Welsh NHS patients in need of proton therapy treated at the centre in Newport. A partnership was also signed between the Rutherford Cancer Centre North East in Northumberland and the Northumbria Healthcare NHS Trust which sees NHS patients from the North East treated at the Northumberland centre for chemotherapy.

The Rutherford Cancer Centres feature the most advanced technologies and Rutherford Health Plc has formed a partnership with IBA (Ion Beam Applications), the world's leading provider of proton beam therapy solutions and Philips, a leader in health technology.

All centres offer proton beam therapy to medically-insured private patients, self-paying patients and NHS patients where the Rutherford is commissioned to provide these services.

For more information on the Rutherford Cancer Centres, please visit: http://www.therutherford.com

Follow the Rutherford Cancer Centres on twitter: @therutherford_c

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NEXUSRRRRAUURAR

(END) Dow Jones Newswires

February 04, 2020 05:05 ET (10:05 GMT)